AMPK activation and depression of LXRα activity are effective therapeutic approaches to protect against obesity, lipid metabolic disorder, and NASH (Griffett et al., 2015; Garcia and Shaw, 2017; Zhao et al., 2020). The gene discussed is NR1H3; the disease is metabolic dysfunction-associated steatohepatitis.